EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Klinische Studie (Phase I)Open Access · CC BY 4.0

Tri-APBI: Single-Institution Phase I/II Prospective Clinical Trial of 3-Fraction Accelerated Partial Breast Irradiation for Stage 0-I Breast Cancer

William R Kennedy, Silpa Raju-Salicki, Maria A Thomas, Jacqueline E Zoberi, Jose Garcia, Domenic Sievert, Mustafaa Mahmood, Julie Margenthaler, Amy Cyr, Pamela Samson, Nusayba A Bagegni, Lindsey Brunt und 1 weitere

Practical Radiation Oncology · 2026-11 · 16 (6) · e473-e482

DOI: 10.1016/j.prro.2026.05.011 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Practical Radiation Oncology, 2026-11. Verfasst von William R Kennedy und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Barrow Neurological Institute, Phoenix, Arizona. Hauptthemen laut MEDLINE: Breast Neoplasms, Brachytherapy. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Siteman Cancer Center.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: This study aims to report safety, feasibility, toxicity, cosmetic, and quality-of-life (QOL) outcomes of a single-institutional prospective phase I/II clinical trial evaluating a novel 3-fraction accelerated partial breast irradiation (Tri-APBI) regimen. METHODS AND MATERIALS: From August 2018 to March 2021, 75 patients with low-risk hormone-sensitive, human epidermal growth factor receptor 2 (HER-2)-negative breast cancer were enrolled on Tri-APBI, delivered with high-dose-rate (HDR) brachytherapy (22.5 Gy in 3 fractions) or external beam radiation therapy (EBRT) (25.5 Gy in 3 fractions) over 2 to 3 days. Modality was chosen by the treating physician. Planning target volume for all patients was created using a 1-cm expansion of breast tissue around the surgical bed, limited by 0.5 cm from the skin surface. RESULTS: Stage I disease was present in 79%, whereas the remainder had ductal carcinoma in situ. Tri-APBI was delivered with EBRT in 44 patients (59%) and HDR in 31 (41%). At a median follow-up of 49 months (IQR, 42-55 months), there were 2 ipsilateral breast tumor recurrences, cumulatively 2.6%, both successfully salvaged. There were no axillary or distant recurrences. There was no Common Terminology Criteria for Adverse Events (CTCAE) v4.0 grade 2+ toxicity observed. Good-to-excellent pretreatment cosmesis was present in 94% and 99% by patient and physician rating, respectively, and in 91% and 98% at the latest follow-up. Quantitative cosmesis assessed by percentage of breast retraction assessment (pBRA) showed that breast asymmetry did not worsen compared with pretreatment, with a baseline mean pBRA of 8.1% (CI, 4.1%-12%) and a 24-month mean pBRA of 6.1% (CI, 4.0%-8.1%). Tri-APBI did not negatively impact most domains of patient-reported QOL, except breast symptom burden at 48 and 60 months and sexual functioning at 36 months only. CONCLUSIONS: Tri-APBI as delivered with EBRT or HDR in this trial was feasible and well-tolerated, with low ipsilateral breast tumor recurrence rates at 4 years and minimal impact on patient-reported QOL, qualitative, and quantitative cosmesis. Further follow-up is needed to evaluate long-term oncologic efficacy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsBrachytherapyHumansFemaleMiddle AgedProspective StudiesAgedAdultDose Fractionation, RadiationNeoplasm StagingQuality of LifeAged, 80 and over

Autor:innen und Institutionen

  • Department of Radiation Oncology, Barrow Neurological Institute, Phoenix, Arizona.
  • Department of Radiation Oncology, WashU Medicine, St. Louis, Missouri.
  • Department of Surgery, Surgical Oncology, WashU Medicine, St. Louis, Missouri.
  • Department of Medicine, Medical Oncology, WashU Medicine, St. Louis, Missouri.
  • Department of Radiation Oncology, WashU Medicine, St. Louis, Missouri. Electronic address: izoberi@wustl.edu.

Förderung

  • Siteman Cancer Center

Zitieren

APA

Kennedy, W. R., Raju-Salicki, S., Thomas, M. A., Zoberi, J. E., Garcia, J., Sievert, D., Mahmood, M., Margenthaler, J., Cyr, A., Samson, P., Bagegni, N. A., Brunt, L., & Zoberi, I. (2026). Tri-APBI: Single-Institution Phase I/II Prospective Clinical Trial of 3-Fraction Accelerated Partial Breast Irradiation for Stage 0-I Breast Cancer. Practical Radiation Oncology, 16(6), e473-e482. https://doi.org/10.1016/j.prro.2026.05.011

Vancouver

Kennedy WR, Raju-Salicki S, Thomas MA, Zoberi JE, Garcia J, Sievert D, et al. Tri-APBI: Single-Institution Phase I/II Prospective Clinical Trial of 3-Fraction Accelerated Partial Breast Irradiation for Stage 0-I Breast Cancer. Practical Radiation Oncology. 2026;16(6):e473-e482. doi:10.1016/j.prro.2026.05.011

BibTeX
@article{Kennedy2026,
  author = {Kennedy, William R and Raju-Salicki, Silpa and Thomas, Maria A and Zoberi, Jacqueline E and Garcia, Jose and Sievert, Domenic and Mahmood, Mustafaa and Margenthaler, Julie and Cyr, Amy and Samson, Pamela and Bagegni, Nusayba A and Brunt, Lindsey and Zoberi, Imran},
  title = {Tri-APBI: Single-Institution Phase I/II Prospective Clinical Trial of 3-Fraction Accelerated Partial Breast Irradiation for Stage 0-I Breast Cancer},
  journal = {Practical Radiation Oncology},
  year = {2026},
  volume = {16},
  number = {6},
  pages = {e473--e482},
  doi = {10.1016/j.prro.2026.05.011}
}
Kostenlos starten →